Your browser doesn't support javascript.
loading
Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Pan, Weidong; Lahue, Brian R; Ma, Yao; Nair, Latha G; Shipps, Gerald W; Wang, Yaolin; Doll, Ronald; Bogen, Stéphane L.
  • Pan W; Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States.
  • Lahue BR; Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, United States.
  • Ma Y; Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, United States.
  • Nair LG; Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States.
  • Shipps GW; Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, United States.
  • Wang Y; Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States.
  • Doll R; Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States.
  • Bogen SL; Merck Research Laboratories, Early Development and Discovery Sciences, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States. Electronic address: Stephane.bogen@merck.com.
Bioorg Med Chem Lett ; 24(8): 1983-6, 2014 Apr 15.
Article en En | MEDLINE | ID: mdl-24656661
ABSTRACT
The discovery of 3,3-disubstituted piperidine 1 as novel p53-HDM2 inhibitors prompted us to implement subsequent SAR follow up directed towards piperidine core modifications. Conformational restrictions and further functionalization of the piperidine core were investigated as a strategy to gain additional interactions with HDM2. Substitutions at positions 4, 5 and 6 of the piperidine ring were explored. Although some substitutions were tolerated, no significant improvement in potency was observed compared to 1. Incorporation of an allyl side chain at position 2 provided a drastic improvement in binding potency.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperidinas / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas c-mdm2 Límite: Humans Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperidinas / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas c-mdm2 Límite: Humans Idioma: En Año: 2014 Tipo del documento: Article